Navigation Links
AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
Date:3/6/2009

ificant long-term revenue for the Company while building value for our shareholders," said Juergen Engel, Ph.D., President and CEO of AEterna Zentaris.

About the Phase 3 Program with Cetrorelix in BPH

Cetrorelix pamoate is currently in three Phase 3 trials involving more than 1,600 patients with symptomatic BPH in Canada, the United States and Europe.

The first multi-center efficacy study for which patient recruitment was completed in April 2008, is currently being conducted primarily in the United States and Canada, with additional sites in Europe and involves 667 patients under the supervision of lead investigator, Herbert Lepor, MD, Professor at NYU School of Medicine, New York. Patients enter a 4-week run-in no-treatment observation period to confirm severity and stability of voiding symptoms based on the International Prostate Symptom Score (IPSS). Patients are then randomly allocated to cetrorelix or placebo in a double-blind fashion. Patients are administered cetrorelix by intra-muscular (IM) injection at Week 0, 2, 26 and 28 and are followed up to Week 52. Then, in an open-label extension, patients receive cetrorelix by IM injection at Week 52, 54, 78 and 80 and are followed up to Week 90.

The second multi-center Phase 3 efficacy study for which patient recruitment was completed in October 2008, involves 420 patients, mainly in Europe. Patients in this randomized placebo-controlled study with open-label extension conducted under the supervision of lead investigator, Prof. Frans M.J. Debruyne, MD, of the Andros Mannenkliniek, Arnhem, The Netherlands, receive cetrorelix according to similar dosing regimens used in the first study.

The primary endpoint for both North American and European efficacy studies is absolute change in IPSS between baseline and Week 52. Other efficacy endpoints include additional measures of BPH symptom progression and the need for BPH-related surgery. Safety endpoints include ch
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
2. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
3. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
4. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
5. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
6. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
7. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
8. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
9. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
11. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 Carahsoft and CDS Federal Services ... 2014 at 2pm EST (11am PST), “Natural Language Processing: ... on how technology can turn raw, heterogeneous data into ... agencies. The online webinar will last approximately one hour. ...
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014 ... analyze and research medicinal plants and therapeutic derivatives ... industry, health professionals, and researchers about the challenges ... (Logo: http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Independent publisher ... California, and Montreal, Canada, has big ideas for 2014 ... The press's goals are to produce high-quality, low-cost, DRM-free ... support local businesses. , The first major development ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... April 20 Quark Pharmaceuticals, Inc., a development-stage ... (RNAi)-based therapeutics, today announced that James D. Thompson, ... presentation on Tuesday, April 20 at this year,s ... Annual Meeting, which is taking place from April ...
... COPENHAGEN, April 20 Santaris Pharma announced ... in vivo activity of microRNA-targeted,therapeutics against cancer ... Locked,Nucleic Acid (LNA) Drug Platform. In both ... cancer targeted LNA-antimiR(R),s demonstrated outstanding,recognition and inhibition ...
... 20 Mpex Pharmaceuticals, Inc. today announced that Mark Wiggins ... Wiggins comes to Mpex from Biogen Idec, Inc. where he ... and was a member of the Executive Committee. At ... development activities related to the company,s lead product, MP-376. ...
Cached Biology Technology:Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting 2Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting 3LNA-Based RNA oligonucleotides Potently Inhibit Cancer microRNAs 2Mpex Pharmaceuticals Names Mark Wiggins Chief Business Officer 2Mpex Pharmaceuticals Names Mark Wiggins Chief Business Officer 3
(Date:4/18/2014)... a twist to the story of how barnyard chickens came ... in the journal Proceedings of the National Academy of ... that lived 200-2300 years ago in Europe, researchers report that ... looked far different from the chickens we know today. , ... with modern domestic chickens -- such as their yellowish skin ...
(Date:4/18/2014)... [Brown University] Asteroid and comet impacts can cause ... regional or even global scales. But new research from ... signatures of ancient life at the time of an ... Pete Schultz has found fragments of leaves and preserved ... ancient impacts in Argentina. The material could provide a ...
(Date:4/17/2014)... the most densely forested and most densely populated quadrant ... human needs, values and practices. Disturbances associated with those ... and development, have set the stage for management issues ... reports. , The report Five anthropogenic factors that ... the Northern United States was published recently ...
Breaking Biology News(10 mins):Ancient DNA offers clues to how barnyard chickens came to be 2Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3
... more corals and fish generate predictably greater levels of ... has important implications for understanding the behaviour of young ... environmental health by listening to reefs. Contrary to ... places, with fish and invertebrates producing clicks and grunts ...
... SALT LAKE CITYResearchers at Huntsman Cancer Institute (HCI) at the ... necessary for the maintenance and repair of the cell,s cytoskeleton, ... of the cell. The research has implications for cancer, as ... often associated with disease. The research was published in the ...
... failure of the Deepwater Horizon oil well last spring, nearly ... of Mexico to contain the spill. While preliminary reports suggest ... effect of such a massive volume of dispersant on ecosystems, ... a University at Buffalo researcher with expertise in how the ...
Cached Biology News:Taking the pulse of coral reefs 2Study offers first explanation of how cells rapidly repair and maintain structure 2A less toxic, more efficient dispersant is scientist's goal 2